· Sevoflurane: relevant cellular effects
· Cardiac muscle
· Smooth muscle
· Skeletal muscle
· ↑activity at GABA-A and glycine receptors -> Cl- influx -> prevent action potential
· ↓L-Ca2+ activity (↓L-Ca2+
· ↑nitric oxide release (↑NO)
· ↓medullary sympathetic outflow (↓SNS)
· ↓nicotinic ACh receptor activity (↓nAChR)
· Most effects are dose-dependent
Contractility Heart rate |
· Direct effect: ↓ o ↑GABA/glycine -> ↓SNS output from medulla o ↓L-Ca2+ channel activity o ↑NO release · Indirect effect: ↑ o Baroreceptor reflex relatively preserved o Reflex tachycardia common |
Anaesthetic preconditioning |
· Activates ATP-sensitive K+ channels in mitochondria and sarcolemma · Mimics ischaemic preconditioning -> ↓risk myocardial ischaemia · Active at MAC >0.25 · Onset in minutes, offset 3-4 days |
↑QT interval |
· ? Mechanism · ↑Risk torsades de pointes (rarely significant) · Sevoflurane, enflurane, isoflurane |
Coronary steal syndrome |
· ↓ L-Ca2+ channel, ↑NO · Awake: o Stenotic vessel maximally dilated o Other vessels mid-dilated o Preserved flow through stenosis · Under GA: o Stenotic vessel no change o Other vessels ↑dilatation o ↓CO, ↓SVR -> ↓aortic root diastolic pressure -> ↓total coronary flow o ↓flow through stenosis · Rarely significant · Isoflurane > others due to greater reduction in SVR |
Mechanism |
· ↓L-Ca2+, ↑NO, ↓SNS |
Systemic vasodilatation |
· Arteries: ↓SVR, ↓mAP; ↑heat loss · Veins: ↓preload -> cardiac output; easier to cannulate |
Pulmonary vasodilatation |
· ↓PVR, ↓HPV, ↑V/Q mismatch, ↓PaO2 |
Cerebral vasodilatation |
· Overrides ↓CMRO2 at >1MAC · Risk of ↑ICP concomitant intracranial pathology |
Bronchodilatation |
· ↓Airway resistance · Used in status asthmaticus |
Uterine relaxation |
· ↑Bleeding during GA Caesarean (hence supplement with N2O, propofol) |
Mechanism |
· CNS and α-motor neurons: ↑GABA-A, ↑glycine · Pre-synaptic: ↓L-Ca2+ -> ↓ACh release · Post-synaptic: ↓nAChR |
Immobility |
· Potentiates paralytics · Facilitates surgery |
Hypoventilation |
· Relaxation of intercostals > diaphragm · Depression of chemoreceptors and respiratory centre · ↓↓Response to ↓PaO2 · ↓Response to ↑PaCO2 |
Airway obstruction |
· ↓Pharyngeal dilator tone · Need for airway device |
Malignant hyperthermia |
· Rare, life-threatening hypermetabolic reaction to volatile anaesthetics or suxamethonium · Mutation in RYR1 gene encoding skeletal muscle ryanodine receptor · Continuous Ca2+ release from SR causing continuous contraction · Idiosyncratic, not dose-dependent like all the above |
Feedback welcome at ketaminenightmares@gmail.com